March 15, 2007 -- The nation’s biggest biotechs could soon be feeling more heat. Their products are now under increased scrutiny because of more widespread use, giving rise to more concerns regarding toxicity and safety. But that is not the only thing that could spell trouble for the current business model of Big Biotech. Two other problems are also well known but often ignored. The first issue is biogenerics, or biosimilar products, and the second is the high prices of biotech drugs. We look at the problems that Big Biotech is facing...
